§ 312.55. Informing investigators.
127 words·~1 min read·
/us/cfr/t21/s§ 312.55·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Before the investigation begins, a sponsor (other than a sponsor-investigator) shall give each participating clinical investigator an investigator brochure containing the information described in § 312.23(a)(5).
(b)The sponsor shall, as the overall investigation proceeds, keep each participating investigator informed of new observations discovered by or reported to the sponsor on the drug, particularly with respect to adverse effects and safe use. Such information may be distributed to investigators by means of periodically revised investigator brochures, reprints or published studies, reports or letters to clinical investigators, or other appropriate means. Important safety information is required to be relayed to investigators in accordance with § 312.32. [52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 67 FR 9586, Mar. 4, 2002]
Connections3 cite this
Cited by 3 sections
Citation graph
cites case law
§ 312.55
Informing investigators.
Fed. Reg.×3
Cites 0Cited by 3 across 1 source